The expression of tumor-cell proliferation markers will be decreased, resulting in apoptosis.16, 17Numerous investigators have evaluated the expression of COX-2 in various cancers, including prostate cancer,18breast cancer,19hepatocellular cancer,20non-small cell lung cancer,21gastrointestinal malignancies,22hematological cancer,23and head and neck tumorigenesis.9However, there is still insufficient clinical data to determine the clinical significance of COX-2 in gliomas. Here, PTGS2 is linked to central nervous system cancer.